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Abstract
Introduction The overall prognosis of critically ill patients with
cancer has improved during the past decade. The aim of this
study was to identify early prognostic factors of intensive care
unit (ICU) mortality in patients with cancer.
Methods We designed a prospective, consecutive,
observational study over a one-year period. Fifty-one cancer
patients with septic shock were enrolled.
Results The ICU mortality rate was 51% (26 deaths). Among
the 45 patients who benefited from transthoracic
echocardiography evaluation, 17 showed right ventricular
dysfunction, 18 showed left ventricular diastolic dysfunction, 18
showed left ventricular systolic dysfunction, and 11 did not
show any cardiac dysfunction. During the first three days of ICU
course, N-terminal pro-brain natriuretic peptide (NT-proBNP)
levels were significantly higher in patients presenting cardiac
dysfunctions compared to patients without any cardiac
dysfunction. Multivariate analysis discriminated early prognostic
factors (within the first 24 hours after the septic shock
diagnosis). ICU mortality was independently associated with
NT-proBNP levels at day 2 (odds ratio, 1.2; 95% confidence
interval, 1.004 to 1.32; p = 0.022). An NT-proBNP level of more
than 6,624 pg/ml predicted ICU mortality with a sensitivity of
86%, a specificity of 77%, a positive predictive value of 79%, a
negative predictive value of 85%, and an accuracy of 81%.
Conclusion We observed that critically ill cancer patients with
septic shock have an approximately 50% chance of survival to
ICU discharge. NT-proBNP was independently associated with
ICU mortality within the first 24 hours. NT-proBNP could be a
useful tool for detecting high-risk cancer patients within the first
24 hours after septic shock diagnosis.
Introduction
The overall prognosis of critically ill patients with cancer has
improved during the past decade [1,2]. Reports concerning
critically ill patients with malignancies admitted to the intensive
care unit (ICU) include a wide range of causes, including sep-
tic shock. In this population, mortality rates tend to be approx-
imately 50% when septic shock is present [2,3]. Despite the
presence of life-threatening factors such as neutropenia or
bone marrow transplantation, prognostic factors in the devel-
opment of septic shock in patients with cancer are related
mainly to the importance of organ dysfunctions [2]. Septic
shock is commonly associated with myocardial dysfunction
[4], for which accurate evaluation at bedside is not easy. In
fact, patients with septic shock show reversible left ventricular
systolic dysfunction (LVSD) often masked by a concomitant
elevation in the cardiac index [5]. Cardiac troponins and natri-
uretic peptides are commonly used for diagnosis and risk
stratification in patients with acute coronary syndrome and
congestive heart failure. Their prognostic and diagnostic rele-
vance is still under investigation in patients with septic shock
[6]. The pro-brain natriuretic peptide (proBNP) is produced by
atrial and ventricular myocytes in response to wall stress [7].
On secretion, the precursor molecule proBNP is split into N-
terminal proBNP (NT-proBNP) and the physiologically active
A = atrial filling wave velocity; Am = myocardial atrial velocity; CI = confidence interval; cTnI = cardiac troponin I; E = early filling wave velocity; Ea = 
myocardial early diastolic velocity; HSCT = hematopoietic stem cell transplantation; ICU = intensive care unit; LOD = logistic organ dysfunction; 
LVDD = left ventricular diastolic dysfunction; LVEF = left ventricular ejection fraction; LVSD = left ventricular systolic dysfunction; NT-proBNP = N-
terminal pro-brain natriuretic peptide; PAH = pulmonary arterial hypertension; PASP = pulmonary artery systolic pressure; proBNP = pro-brain natri-
uretic peptide; ROC = receiver operating characteristic; RVD = right ventricular dysfunction; TTE = transthoracic echocardiography.Critical Care    Vol 11 No 2    Mokart et al.
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C-terminal peptide comprising 32 amino acids (BNP). Plasma
BNP and NT-proBNP measurements are useful in diagnosing
systolic [8] and diastolic [9] heart failure, and their concentra-
tions have been shown to be predictive of mortality in patients
with septic shock [10]. Moreover, in patients with cancer, a
persistent increase of NT-proBNP early after administration of
high-dose chemotherapy is strongly associated with the devel-
opment of cardiac dysfunction [11]. In patients with cancer,
septic shock remains associated with a high risk of death, and
early evaluation and treatment are essential for maximizing the
chance of recovery. The aim of this study was to investigate
early prognostic factors in patients with cancer who devel-
oped septic shock.
Materials and methods
The study was conducted prospectively over a 13-month
period in a cancer hospital. ICU admission occurred between
1 December 2004 and 16 December 2005. After receiving
approval from our institutional ethics committee and obtaining
the informed consent of the patients or next of kin, we per-
formed the study in 51 consecutive adult cancer patients with
medical septic shock. Septic shock was defined according to
the criteria of the American College of Chest Physicians/Soci-
ety of Critical Care Medicine Consensus Conference [12,13]:
(a) clinical evidence of infection, (b) tachycardia (more than 90
beats per minute), (c) tachypnea (more than 20 breaths per
minute) or the need for mechanical ventilation, (d) refractory
hypotension defined by a sustained decrease in systolic blood
pressure below 90 mm Hg despite fluid replacement (40 ml/
kg) or the use of a vasopressor to maintain systolic blood pres-
sure above 90 mm Hg, and (e) evidence of inadequate organ
function or perfusion within 12 hours of enrollment, as mani-
fested by at least one of the following syndromes: acute alter-
ation of mental status, arterial hypoxemia (PaO2/FiO2 [arterial
partial pressure of oxygen/fraction of inspired oxygen] of less
than 280), plasma lactate concentrations above the normal
range or metabolic acidosis, oliguria defined by a urine output
of less than 0.5 ml/kg per hour, or disseminated intravascular
coagulation.
Exclusion criteria included age of less than 18 years and
chronic illnesses known to increase NT-proBNP levels, such
as chronic heart insufficiency defined by a left ventricular ejec-
tion fraction (LVEF) of less than 45% or valvular heart disease,
chronic obstructive lung disease, pre-existent renal insuffi-
ciency (history of serum creatinine of more than 180 μmol/l
before the onset of septic shock), and brain disorders.
Patients with septic shock were systematically admitted to the
ICU once the diagnosis was performed. They came from
hematology or oncology units. All patients benefited from
broad-spectrum antibiotic treatment (betalactamin plus an
aminoside or a quinolone plus a glycopeptide) immediately
after the initial clinical evaluation. All patients also benefited
from standard supportive care for the shock according to the
Surviving Sepsis Campaign [14] once they had been man-
aged by the physician. Fluid expansion (using crystalloids or
colloids) was firstly used to increase blood pressure. Then, the
use of epinephrine, norepinephrine, and/or dobutamine was
decided by the physician in charge of the patient. Stress-dose
steroids were routinely administered in our patients presenting
septic shock. Hemodynamic exploration, using echocardiogra-
phy or a Swan-Ganz catheter, was routinely performed in all
patients presenting septic shock.
Standard biological data were prospectively collected during
the ICU stay. The following clinical data were prospectively
collected during the ICU stay: age and gender; chronic health
status as evaluated using the Charlson comorbidity index [15];
characteristics of the malignancy, including the number of pre-
vious courses of chemotherapy and current status (complete
or partial remission); neutropenia (white blood cell count of
less than 1,000 leukocytes per cubic millimeter and/or neu-
trophil count of less than 500 per cubic millimeter); infection
category (clinically documented infection or microbiologically
documented infection); severity-of-illness scores using Simpli-
fied Acute Physiology Score II at admission [16]; and Logistic
Organ Dysfunction (LOD) score on day 1 (day of septic shock
diagnosis) and day 2 [17]; the presence of persistent organ
dysfunctions of more than 48 hours according to the LOD
score; therapeutic interventions, including vasopressor use,
inotrope use, mechanical ventilation, duration of mechanical
ventilation, renal replacement therapy, duration of renal
replacement, length of ICU stay; and time from sepsis diagno-
sis to ICU admission and time from ICU admission to septic
shock diagnosis and ICU mortality. Early prognostic factors
were defined as easy-to-collect, clinical and biological factors
available at bedside within the first 24 hours after the septic
shock diagnosis (days 1 and 2).
Echocardiographic evaluation
In our ICU, right catheterization is rarely performed and tran-
sthoracic echocardiography (TTE) is commonly used to
assess the hemodynamic status of critically ill patients. TTE
was performed daily during the septic shock course but not
necessarily at the same time as the NT-proBNP measurement.
Forty-five (88%) patients received daily TTE evaluation of left
and right ventricular function, and six patients could not be
evaluated because of their bad echogenicity. TTE was per-
formed using a commercially available ultrasound machine,
Acuson 'Cypress' (Acuson Corp., part of Siemens AG,
Munich, Germany). Conventional M-mode and two-dimen-
sional echocardiographic measurements were performed
according to the guidelines of the American Society of
Echocardiography [18,19]. In accordance with Simpson's
method of estimation of ejection fraction, the LVEF was
divided into two groups: normal or slightly reduced (ejection
fraction of greater than 45%) and reduced (ejection fraction of
less than 45% = LVSD). Left ventricular diastolic dysfunction
(LVDD) (that is, impaired relaxation, pseudonormal pattern,Available online http://ccforum.com/content/11/2/R37
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and restrictive pattern) was suggested by alterations in the
Doppler mitral flow (ratio of early filling wave velocity [E] to
atrial filling wave velocity [A]) and/or alterations in myocardial
early diastolic velocity (Em) and myocardial atrial velocity (Am)
by tissue Doppler at lateral mitral annulus resulting in modifica-
tions of the Em/Am ratio [20,21] (Table 1). The mitral inflow
velocity was recorded from the apical four-chamber view with
the pulsed-wave Doppler sample volume positioned between
the tips of the mitral leaflets during diastole. E and A of mitral
inflow were obtained. Septic right ventricular dysfunction
(RVD) was defined as suggested by Vieillard-Baron and col-
leagues [4]. Briefly, RVD was defined as a septal dyskinesia
and a dilatation of the right ventricle (end-diastolic diameter of
more than 30 mm from the parasternal view or the right ventri-
cle appearing larger than the left ventricle from the subcostal
or apical view) or the association of right ventricle dilatation
and pulmonary arterial hypertension (PAH). PAH was defined
as a pulmonary artery systolic pressure (PASP) of more than
45 mm Hg. The echocardiographic assessment of the PASP
was made by the modified Bernoulli equation (P = 4V2 + right
atrial pressure, where P was the peak pressure gradient
between the right atrium and the right ventricle, V was the
peak velocity of the tricuspid regurgitant jet, and right atrial
pressure was assimilated to central venous pressure). Cardiac
dysfunctions were defined as the presence of LVSD, LVDD, or
RVD for more than 48 hours.
Assay for N-terminal pro-brain natriuretic peptide
Plasma levels of NT-proBNP were measured at septic shock
diagnosis (day 1) and on days 2 and 3. The venous blood sam-
ples were collected in 10-ml vacutainers containing lithium-
heparin (Becton Dickinson Biosciences, San Jose, CA, USA),
which were placed on ice and transported to our laboratory for
immediate assay. The samples were centrifuged at 3,000g for
10 minutes. NT-proBNP values were determined by an elec-
trochemiluminescence sandwich immunoassay with an Elec-
sys 2010 instrument (Roche Diagnostics GmbH, Mannheim,
Germany). The interassay coefficients of variation are 3.2% at
175 pg/ml, 2.9% at 355 pg/ml, and 2.6% at 1,068 pg/ml [22].
The analytical range extends from 20 to 35,000 pg/ml. Upper
values are obtained by diluting samples. The total duration of
the assay was 18 minutes.
Assay for cardiac troponin I
Plasma levels of cardiac troponin I (cTnI) were measured on
days 1, 2, and 3. The venous blood samples were collected in
10-ml vacutainers containing lithium-heparin (Becton Dickin-
son), which were placed on ice and transported to our labora-
tory for immediate assay. The samples were centrifuged at
3,000g for 10 minutes. For the measurement of cTnI, we used
a sandwich immunoassay test (Dade Behring, Inc., Deerfield,
IL, USA) on the Dimension RxL analyzer(Dade Behring,
Newark, DE, USA). The upper limit of normal for cTnI was set
at 0.2 μg/l. The values of interassay imprecision were 7.6% at
0.27 μg/l and 8.1% at 28.3 μg/l [23].
Statistical analysis
Categorical data are presented as number (percentage).
Quantitative data are presented as median (25th to 75th per-
centiles). Statistical analysis was performed using SPSS soft-
ware (version 12.0; SPSS Inc., Chicago, IL, USA). Univariate
analysis was conducted to determine prognostic factors for
the occurrence of ICU death after septic shock. All the param-
eters collected in Table 2 were considered for univariate anal-
ysis. Chi-square tests or Fisher exact tests were used for
qualitative variables. The Mann-Whitney test was used for con-
tinuous variables. To investigate the correlations between two
single variables, Spearman rank correlation was performed. A
multivariate analysis was conducted to quantify the respective
role of each variable on the occurrence of ICU death. A step-
wise logistic regression was performed (backward method).
The explanatory variables included in the logistic regression
were variables identified as potential prognostic factors by the
univariate analysis (cutoff p < 0.05). To avoid increasing the
risk of collinearity for the same variables measured at days 1
and 2 (LOD and NT-proBNP), we decided to include only the
most significant of them in the logistic regression analysis
because these variables are often highly correlated [24,25].
The condensed model was presented with odds ratio and
95% confidence interval (CI). In regard to NT-proBNP, dis-
Table 1
Doppler echocardiographic pattern in relation to the diagnosis and the grading of left ventricular diastolic dysfunction
Left ventricular diastolic dysfunction
Parameter Normal pattern Pattern of abnormal relaxation Pseudonormal pattern Restrictive pattern
E/A > 1 < 1 1–2 > 2
Ea (cm/s) > 8 < 8 < 8 < 5
E/Ea < 8 > 16
E/A, ratio of transmitral early filling wave velocity to atrial filling wave velocity; Ea, myocardial early diastolic velocity by tissue Doppler at lateral 
mitral annulus; E/Ea, ratio of transmitral early diastolic velocity to myocardial early diastolic velocity of lateral mitral annulus by tissue Doppler.Critical Care    Vol 11 No 2    Mokart et al.
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crimination was assessed using the area under the receiver
operating characteristic (ROC) curve to evaluate how well the
model distinguished patients who died in the ICU. Cumulative
survival rates in patients with septic shock according to the
cutoff value of NT-proBNP are presented by Kaplan-Meier dia-
gram, and differences among groups were tested by the log-
rank test. The required significance level was set at a p value
of less than 0.05.
Results
Our study included 51 patients, 32 men (63%) and 19 women
(37%). Patients were a median of 56 (50 to 68) years old. The
characteristics of the patients are reported in Table 3. Eight-
een patients (35%) presented acute leukemia, 16 patients
(31%) presented a lymphoma, 11 patients (21%) presented a
solid tumor, and 6 patients (12%) presented myelodysplastic
syndrome. Twenty patients (39%) were neutropenic, and 11
received hematopoietic stem cell transplantation (HSCT)
(21%). Forty-three patients (84%) benefited from recent
chemotherapy; of these, 28 (65%) were treated with anthracy-
clins. During the ICU course, respiratory dysfunction was
present in 48 patients (94%), neurologic dysfunction was
present in 16 patients (31%), hepatic dysfunction was present
in 27 patients (53%), and renal dysfunction was present in 26
patients (51%). The ICU mortality rate was 51% (26 deaths).
The univariate analysis showed that NT-proBNP levels, LOD
score, and cTnI levels were significantly associated with ICU
mortality. Among the characteristics of the malignancies,
autologous HSCT was the only parameter associated with
ICU mortality (Table 2). The multivariate analysis showed that
only NT-proBNP level at day 2 was an early independent factor
of ICU mortality (Table 2). When gender and age, which are
known to influence NT-proBNP, were introduced in the step-
Table 2
Early prognostic factors for ICU mortality, univariate and multivariate analysis
Survivors (n = 25) Non-survivors (n = 26) p value
NT-proBNP in pg/ml on day 1 3,414 (754–9,005) 7,939 (4,495–33,662) 0.0015
NT-proBNP in pg/ml on day 2 3,145 (990–6,490) 13,091 (8,132–40,627) < 0.0001
cTnI in μg/l on day 1 0.05 (0.0–0.168) 0.155 (0.090–0.290) 0.03
cTnI in μg/l on day 2 0.04 (0.020–0.210) 0.125 (0.105–0.190) 0.08
LOD score on day 1 7 (6–9) 10 (9–12) 0.0002
LOD score on day 2 5 (4–6) 8 (5–9) 0.0009
SAPS II at ICU admission on day 1 50 (41–60) 48 (35–82) 0.49
Lactate in mmol/l on day 1 1.8 (1.3–2.9) 3.0 (1.6–6.8) 0.14
Lactate in mmol/l on day 2 1.8 (1.3–2.6) 2.6 (1.4–4.8) 0.22
Charlson comorbidity index 2 (2–4) 3 (2–4) 0.76
Age in years 58 (47–68) 55 (51–70) 0.65
Male gender 16 (64%) 16 (61.5%) 0.9
Time from sepsis to ICU admission 
in days
2 (0–5) 3 (0–9.75) 0.38
Neutropenia 8 (32%) 12 (46%) 0.4
Anthracyclin treatment 14 (56%) 14 (54%) 0.8
Autologous HSCT 0 (0%) 6 (23%) 0.023
Allogeneic HSCT 2 (8%) 3 (11.5%) 0.9
Lymphoma 6 (24%) 9 (35%) 0.54
Acute leukemia 10 (40%) 8 (31%) 0.56
Multivariate logistic regression P value Odds ratio 95% CI
NT-proBNP in pg/ml on day 2 0.022 1.2 1.004–1.32
Data are expressed as number (percentage) or as median (25th–75th percentiles). p < 0.05 was considered significant. CI, confidence interval; 
cTnI, cardiac troponin I; HSCT, hematopoietic stem cell transplantation; ICU, intensive care unit; LOD, Logic Organ Dysfunction; NT-proBNP, N-
terminal pro-brain natriuretic peptide; SAPS II, Simplified Acute Physiology Score II.Available online http://ccforum.com/content/11/2/R37
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wise logistic regression, the results were the same. Other fac-
tors such as cTnI or lactates were not independently
associated with ICU mortality.
On day 1, NT-proBNP levels were positively correlated to LOD
score (r = 0.39, p = 0.008) and cTnI levels (r = 0.567, p =
0.0005). On day 2, NT-proBNP levels were positively corre-
lated to LOD score (r = 0.565, p = 0.0002) and cTnI levels (r
= 0.480, p = 0.004). An ROC curve was constructed taking
into account NT-proBNP levels on day 2 (Figure 1). An NT-
proBNP level of greater than 6,624 pg/ml predicted ICU mor-
tality with a sensitivity of 86%, a specificity of 77%, a positive
predictive value of 79%, a negative predictive value of 85%,
and an accuracy of 81%. Area under the curve (AUC) was
87% (p < 0.0001, 95% CI 0.768 to 0.976). Kaplan-Meier
analysis (Figure 2) estimates the rate of death within ICU stay
among patients with septic shock according to NT-proBNP
values above or below 6,624 pg/ml (cutoff value as deter-
mined by ROC curve analysis). Differences between the two
groups were significant (p = 0.0011 by the log-rank test).
In the non-survivors and during the first three days of ICU
course, NT-proBNP levels were highest in patients previously
treated with anthracyclines compared to patients without
anthracycline treatment: 33,662 pg/ml (9,410 to 85,015) ver-
sus 5,275 pg/ml (2,953 to 7,939) (p = 0.003), respectively,
on day 1 and 37,435 pg/ml (11,348 to 93,867) versus 10,070
pg/ml (6,157 to 13,520) (p = 0.012), respectively, on day 2.
Table 3
Characteristics of the patients
Number (percentage)
or median (25th–75th percentiles)
Age in years 56 (50–68)
Male gender 32 (62%)
SAPS II at ICU admission 50 (35–71)
LOD score on day 1 10 (6–10)
Time from sepsis to ICU admission in days 2 (0–6)
Time from ICU admission to septic shock in days 0 (0–1)
Norepinephrine treatment 46 (89%)
Epinephrine treatment 23 (45%)
Dobutamine treatment 15 (29%)
Mechanical ventilation 49 (96%)
Duration of mechanical ventilation in days 11 (7–20)
Renal replacement 24 (47%)
Duration of renal replacement in days 1 (0–7)
Type of infection
Pulmonary sepsis 28 (55%)
Abdominal sepsis 8 (15.7%)
Urinary sepsis 1 (2%)
Isolated bacteremia 14 (2 7.5%)
Microorganism
Gram-negative bacilli 18 (35.3%)
Gram-positive cocci 13 (25.5%)
Fungus 9 (17.5%)
Viruses 1 (2%)
Not documented 10 (19.6%)
ICU length of stay in days 18 (10–28)
ICU mortality 26 (50.1%)
ICU, intensive care unit; LOD, Logic Organ Dysfunction; SAPS II, Simplified Acute Physiology Score II.Critical Care    Vol 11 No 2    Mokart et al.
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In the survivors and during the first three days of ICU course,
NT-proBNP levels were similar in patients previously treated
with anthracyclines and in patients without anthracycline treat-
ment: 3,498 pg/ml (768 to 8,425) versus 1,396 pg/ml (886 to
8,866), respectively, on day 1 and 4,041 pg/ml (1,246 to
8,195) versus 2,537 pg/ml (914 to 4,170), respectively, on
day 2.
Among the 45 patients who benefited from TTE evaluation, 17
showed RVD, 18 showed diastolic dysfunction, 18 showed
systolic dysfunction, and 11 did not show any cardiac dysfunc-
tion (no cardiac dysfunction group). On day 2, NT-proBNP
level was higher in patients presenting cardiac dysfunction but
was not higher on day 1 (Table 4). During the ICU course, only
the occurrence of RVD was significantly associated with ICU
mortality. The same, but non-significant, trend was observed
when LVDD was present (Table 5).
Discussion
This study was conducted to determine early prognostic fac-
tors in the development of septic shock in patients with can-
cer. We found that the ICU mortality in such patients was
similar to that observed in the general population. After full life
support management, NT-proBNP on day 2 was an early inde-
pendent factor of ICU death.
Septic shock is often accompanied by pronounced hemody-
namic dysfunction. This dysfunction is associated with left ven-
tricular dysfunction, peripheral vasodilatation resulting in
systemic hypotension, hyporesponsiveness to vasopressors,
and a reduced vascular resistance. Actually, cardiac dysfunc-
tion during septic shock can variably be associated with left
and right dysfunction [4,5,26] and systolic and diastolic dys-
function [27,28]. In this situation, high levels of NT-proBNP are
associated with poor prognosis and severe cardiac dysfunc-
tion [10,29]. Patients treated with doxorubicin chemotherapy
exhibit high levels of natriuretic peptides. This may be related
to a severe impairment of both systolic and diastolic dysfunc-
tion [30]. Among the study group, 45 patients received
echocardiographic evaluation and 34 (75.5%) of them
showed cardiac dysfunction. Eighteen (40%) of them showed
LVSD, 18 (40%) showed LVDD, and 17 (38%) showed RVD.
A striking finding from this study is that the cutoff value of NT-
proBNP to detect high-risk patients in the first 24 hours was
two times lower in patients with cancer than in the general
population [10]. However, the NT-proBNP value chosen by
Roch and colleagues [10] was the highest value of four meas-
urements performed during the first 48 hours, which could
account, in part, for the discrepancies with our results. Never-
theless, our results also suggest that, in the context of septic
shock, patients with cancer are more vulnerable to cardiomyo-
cyte stretch than the general population. Fifty-five percent of
our patients were treated with a chemotherapy that included
Figure 2
Kaplan-Meier curve for N-terminal pro-brain natriuretic peptide (NT- proBNP) at the cutoff value of 6,624 pg/ml Kaplan-Meier curve for N-terminal pro-brain natriuretic peptide (NT-
proBNP) at the cutoff value of 6,624 pg/ml. Kaplan-Meier analysis esti-
mates the rate of death within intensive care unit (ICU) stay among sep-
tic shock patients according to NT-proBNP values above or below 
6,624 pg/ml (cutoff value as determined by receiver operating charac-
teristic curve analysis). The differences between the two groups were 
significant (p = 0.0011 by the log-rank test).
Figure 1
Receiver operating characteristic curve for N-terminal pro-brain natriu- retic peptide (NT-proBNP) Receiver operating characteristic curve for N-terminal pro-brain natriu-
retic peptide (NT-proBNP). Receiver operating characteristic curve for 
determination of NT-proBNP levels as a graphic representation of the 
relationship between sensitivity (true-positive rate) and 1 - specificity 
(false-positive rate). The area under the curve for NT-proBNP (area 
under the curve, 0.87; p < 0.0001) summarizes the capacity of NT-
proBNP as a valuable predictor of mortality of patients with septic 
shock.Available online http://ccforum.com/content/11/2/R37
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anthracycline before the onset of septic shock. Furthermore, in
the non-survivor group, NT-proBNP levels were markedly
increased in patients previously treated with anthracycline
compared to patients without anthracycline treatment
whereas no difference was found in the survivor group. Taken
together, our findings presume that the occurrence of septic
shock-related cardiac dysfunction could be precociously and
dramatically worsened by a pre-existing chemotherapy-
induced cardiomyopathy in certain patients with cancer. In
addition, we showed that NT-proBNP levels were significantly
correlated to elevated levels of cTnI. In accordance with previ-
ous reports [31], 62% of our patients showed cTnI levels
greater than the threshold of myocardial damage (> 0.1 ng/ml)
within the first 24 hours (data not shown). Natriuretic peptides
and cardiac troponins provide subtle pieces of information
about cardiac dysfunction. Natriuretic peptide release reflects
wall stress and thus provides information about the functional
status of myocardium, whereas troponin release attests to
myocyte injury [6]. Increased levels of both cTnI and NT-
proBNP have been found in patients with severe sepsis, and a
good correlation between these two markers seems to indi-
cate a relationship between the degree of myocyte damage
and functional myocardial impairment [29]. NT-proBNP might
be a useful tool for detecting sepsis-induced cardiac dysfunc-
tions. At the cutoff value of 6,624 pg/ml, NT-proBNP within
the first 24 hours could permit the detection of the high-risk
mortality population in cancer patients presenting septic
shock. However, the contribution of NT-proBNP in quantifying
the risk of death should be evaluated in larger studies.
At the time of septic shock diagnosis (day 1), the levels of NT-
proBNP were high. Moreover, these levels were not associ-
ated with the occurrence of cardiac dysfunctions (RVD, LVSD,
or LDVD). Interestingly, patients without cardiac dysfunction
exhibited equally high levels of NT-proBNP, suggesting mech-
anisms other than atrial or ventricular wall stress in the release
of natriuretic peptides [32]. This could also be explained by
the fact that most septic patients exhibit low systemic vascular
resistance associated with unloading of the left ventricle; in
this situation, myocardial depression can be present whereas
echocardiographic assessment may show a preserved LVEF
[6,33]. In contrast, on day 2, NT-proBNP levels were associ-
ated with the occurrence of cardiac dysfunctions. Indeed,
LVSD [34], LVDD [28], and RVD [4] have been found in
patients with sepsis and thus might contribute to increased
NT-proBNP levels [6]. Among cardiac dysfunctions, only RVD
was significantly associated with ICU death. RVD has been
demonstrated in septic shock by means of echocardiography
[4,26]. In agreement with two previous studies using echocar-
diography [35,36], we found that RVD was observed with
echocardiographic evaluation in 38% of the patients. In septic
shock, RVD may be related to intrinsic depression in contrac-
tility, acute cor pulmonale produced by an acute increase in
pulmonary vascular resistance [26], an increase in airway
pressure produced by mechanical ventilation when applied on
a depressed right ventricle, or chemotherapy [37]. Hemody-
namic management of patients presenting RVD remains con-
troversial [38,39], especially with regard to the use of volume
loading, vasopressors, and inotropes. Because these factors
Table 5
Characteristics of cardiac dysfunctions among patients who benefited from transthoracic echocardiography evaluation (n = 45) 
during the intensive care unit course
Survivors (n = 23)a Non-survivors (n = 22)a p value
Right ventricular dysfunction 5 (22%) 12 (54.5%) 0.03
Left ventricular systolic dysfunction 9 (39%) 9 (40.1%) 0.9
Left ventricular diastolic dysfunction 6 (26%) 12 (54.5%) 0.07
No cardiac dysfunction 8 (34.5%) 3 (13.6%) 0.16
aData are expressed as number (percentage).
Table 4
Comparisons of NT-proBNP levels according to the occurrence of cardiac dysfunctions during the intensive care unit course
RVD (n = 17) LVSD (n = 18) LVDD (n = 18) NCD (n = 11)
NT-proBNP in pg/ml on 
day 1
6,138 (3,530–16,458) 6,214 (3,721–30,409) 9,001 (4,000–33,167) 4,220 (488–17,371)
NT-proBNP in pg/ml on 
day 2
7,685 (3,965–23,433)a 9,083 (3,860–22,784)a 11,254 (4,067–37,804)a 914 (447–12,545)
ap < 0.05 compared to the no cardiac dysfunction (NCD) group. Data are expressed as median (25th–75th percentiles). The number of patients 
in whom NT-proBNP was measured on day 2 was the same as on day 1 (no death on day 1). LVDD, left ventricular diastolic dysfunction; LVSD, 
left ventricular systolic dysfunction; NT-proBNP, N-terminal pro-brain natriuretic peptide; RVD, right ventricular dysfunction.Critical Care    Vol 11 No 2    Mokart et al.
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may influence NT-proBNP release [6], one can suppose that
beyond right ventricular wall stress other vital stimuli may
account for NT-proBNP release and influence the outcome.
In the univariate analysis and in agreement with previous data
[2], ICU mortality was more closely associated with the mark-
ers of organ dysfunctions (LOD score) than with cancer sta-
tus. Indeed, malignancy and factors reflecting the
characteristics of malignancy were not independently associ-
ated with ICU mortality. Because the outcome of critically ill all-
ogeneic HCST recipients is poor [40], the lack of a significant
association between these patients and ICU mortality may be
related to the limited sample size of this subgroup of patients.
In the present study, neutropenia was not found to be a pre-
dictor of mortality in cancer patients with septic shock. Few
recent studies have found neutropenic patients to have mortal-
ity rates similar to non-neutropenic patients when septic shock
was present [2,3]. We also confirm this trend. During the last
few years, the mortality rate of septic cancer patients admitted
to the ICU has markedly improved. This may be related to the
early admission of septic patients in the ICU for the purpose of
providing an early goal-directed therapy as recommended by
Rivers and colleagues [41] but also to recent advances in the
treatment of hematologic malignancies and solid tumors [41-
43]. Our study confirms this trend. In our institution, the ICU
admission policy is broad and includes most patients with a
'therapeutic project' regardless of their cancer status. All sep-
tic patients admitted to the ICU benefited from standardized
supportive care according to the Surviving Sepsis Campaign,
including stress-dose steroids and early goal-directed therapy
[14,41,44]. In addition, patients considered to benefit signifi-
cantly from immediate ICU admission were managed system-
atically and daily by both the intensivist and the hematologist/
oncologist until ICU admission. Most of our patients exhibited
a pronounced thrombopenia, and only one of them benefited
from treatment with human recombinant-activated protein C
[45]. Despite this inconvenience, the mortality rate in this pop-
ulation of patients was promising. Because NT-proBNP may
be a valuable early biological marker that allows risk stratifica-
tion of septic shock in patients with cancer, early detection of
high-risk patients could permit us to evaluate new therapeutic
options, including human recombinant-activated protein C.
Our study has several limitations. First, we studied only 51
patients with cancer (of whom 26 died), which is not enough
to develop a predictive scoring system. Hence, further large
studies are required to validate our findings. Second, NT-
proBNP is known to be influenced by hemodynamic parame-
ters such as LVEF or left ventricular stroke work index, which
could also be prognostic factors. In our study, RVD and LVDD
appear as prognostic factors, but because only 45 of our
patients (88%) received an echocardiographic evaluation,
they could not be analyzed as predictive factors in the multivar-
iate analysis. Third, in our ICU, right catheterization is rarely
performed and TTE is commonly used to assess the hemody-
namic status of critically ill patients; this explains the lack of
hemodynamic data.
Conclusion
We observed that critically ill cancer patients with septic
shock have an approximately 50% chance of survival to ICU
discharge. NT-proBNP could be a valuable and useful tool for
detecting high-risk cancer patients within the first 24 hours
after septic shock diagnosis.
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